AVTE | tickerfilter.com

Fundamental analysis

26%

Profitability 0%

Dept financing 11%

Liquidity 50%

Performance 50%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.80%

1 Month

1.21%

3 Months

-1.57%

6 Months

23.04%

1 Year

-91.05%

2 Year

-86.16%

Key data

Stock price

$2.51

P/E Ratio

0.00

DAY RANGE

$2.50 - $2.56

EPS

-$2.44

52 WEEK RANGE

$1.25 - $27.11

52 WEEK CHANGE

-$90.71

MARKET CAP

76.517 M

YIELD

N/A

SHARES OUTSTANDING

28.868 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-12-2025

BETA

0.68

PUBLIC FLOAT

AVERAGE 10 VOLUME

$110,290

AVERAGE 30 VOLUME

$74,718

Company detail

CEO: Timothy P. Noyes
Region: US
Website: aerovatetx.com
Employees: 20
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Aerovate Therapeutics, Inc. focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company is advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.

AVTE - Aerovate Therapeutics, Inc.